Paul Stewart, MD
Retina Specialist · Bellaire, TXNPI 1508028523
Payments from drug & device makers
Across 162 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$546
- Regeneron Healthcare Solutions, Inc.$545
- Astellas Pharma US Inc$299
- Novartis$280
- Johnson & Johnson Surgical Vision, Inc.$213
- Bausch & Lomb Americas Inc.$195
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,82399%
- Education$160%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $546 |
| Regeneron Healthcare Solutions, Inc. | 24 | $545 |
| Astellas Pharma US Inc | 11 | $299 |
| Novartis | 14 | $280 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $213 |
| Bausch & Lomb Americas Inc. | 11 | $195 |
| Sun Pharmaceutical Industries Inc. | 9 | $181 |
| Eyepoint US, Inc. | 1 | $180 |
| Genentech USA, Inc. | 6 | $165 |
| Tarsus Pharmaceuticals, Inc. | 6 | $158 |
| Biogen | 6 | $134 |
| Oyster Point Pharma, Inc. | 6 | $132 |
| Biotissue Holdings Inc. | 6 | $115 |
| Alcon | 5 | $102 |
| Harrow Eye, LLC | 4 | $96 |
| Aerie Pharmaceuticals, Inc. | 3 | $70 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $68 |
| Dompe US, Inc. | 2 | $59 |
| Kala Pharmaceuticals, Inc. | 2 | $54 |
| Carl Zeiss Meditec USA, Inc. | 2 | $42 |
| Alimera Sciences, Inc. | 2 | $37 |
| Immunocore Limited | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Rxsight Inc | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Glaukos Corporation | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YUTIQ$180
How this compares
$3,858 in reported general payments places this provider in the 55th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 55 | $59,122 |
| XiidraLifitegrast | 16 | $18,569 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $17,925 |
| LumiganBimatoprost | 30 | $16,943 |
| Cyclosporine | 18 | $11,451 |
| ProlensaBromfenac Sodium | 25 | $9,357 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $8,325 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 63 | $7,089 |
| Lotemax SmLoteprednol Etabonate | 22 | $5,524 |
| Alphagan PBrimonidine Tartrate | 16 | $5,270 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $4,549 |
| Prednisolone Acetate | 142 | $4,407 |
| Difluprednate | 46 | $3,468 |
| Bromfenac Sodium | 15 | $3,017 |
| Atropine Sulfate | 68 | $2,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $546 | $99,260139 claims |
| Bausch & Lomb Americas Inc.Xiidra | $195 | $18,56916 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $68 | $14,88147 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $70 | $8,32512 claims |
| AlconSimbrinza | $102 | $4,54917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 108 retina specialist providers in Texas.
Other retina specialist in Bellaire
- Emmanuel ChangBellaire$3.7M
- Ting Fang SuarezBellaire$156K
- Angela KimBellaire$7K
- Brian BergerAustin$7.7M
- Richard LaneSan Antonio$4.7M
- Jeremiah BrownSchertz$3M
- Victor GonzalezMcAllen$2.1M
- Courtney CrawfordBurleson$1.2M
- Cecilia SanchezAustin$893K
- Sarah HolySan Antonio$689K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.